Low levels of PCSK9, correlated with higher remission rates in RA patients receiving anti-tumor necrosis factor (TNF)-α therapy, further suggest a role for PCSK9 inhibitors in managing disease activity and CV risk [45]. The gene discussed is PCSK9; the disease is rheumatoid arthritis.